Neuregulin-1β for the treatment of systolic heart failure.

Abstract

The Neuregulin-1 gene encodes a family of ligands that act through the ErbB family of receptor tyrosine kinases to regulate morphogenesis of many tissues. Work in isolated cardiac cells as well as genetically altered mice demonstrates that neuregulin-1/ErbB signaling is a paracrine signaling system that functions in endocardial-endothelial/cardiomyocyte interactions to regulate tissue organization during development as well as maintain cardiac function throughout life. Treatment of animals with cardiac dysfunction with recombinant neuregulin-1beta improves cardiac function. This has led to ongoing early phase clinical studies examining neuregulin-1beta as a potential novel therapeutic for heart failure. In this review we synthesize the literature behind this rapidly evolving area of translational research. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."

• Authors: Douglas B Sawyer, Anthony Caggiano
• Journal: Journal of molecular and cellular cardiology (J Mol Cell Cardiol) Vol. 51 Issue 4 Pg. 501-5 (Oct 2011) ISSN: 1095-8584 [Electronic] England
• PMID: 21729703 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Neuregulin-1
• Recombinant Proteins
• neuregulin beta

Topics

• Animals
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Heart Failure, Systolic (drug therapy)
• Humans
• Neuregulin-1 (physiology, therapeutic use)
• Organ Specificity
• Paracrine Communication
• Recombinant Proteins (therapeutic use)